Bioinnovation and drug discovery at ANSTO’s Australian Synchrotron

ANSTO’s Australian Synchrotron (AS) is a premier national research facility providing Australia, New Zealand and the broader region with access to world-class instrumentation and advanced analytical techniques. Synchrotrons worldwide have established themselves as invaluable tools for drug discovery and biological innovation, and the AS is no different. The Australian Synchrotron’s capabilities provide significant data regarding the molecular and structural dynamics of complex biological systems. These enable insights from mapping drug-target interactions at the atomic level to visualising physiological responses within tissues and organisms. The following article outlines these capabilities and their application to drug discovery in more detail.

Authors

Institutions

Publication Details

Journal
Microbiology Australia
Published
2025-05-26
DOI
https://doi.org/10.1071/ma25023
Primary Topic
Genetics, Bioinformatics, and Biomedical Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bioinnovation and drug discovery at ANSTO’s Australian Synchrotron

Rachel Williamson, Emily G. Finch, Helen E. A. Brand, Ashish Sethi et al.
Microbiology Australia
Genetics, Bioinformatics, and Biomedical Research
article

Bioinnovation and drug discovery at ANSTO’s Australian Synchrotron

Rachel Williamson, Emily G. Finch, Helen E. A. Brand, Ashish Sethi, Danielle E. Martin, Daniel Häusermann
article en

Abstract

ANSTO’s Australian Synchrotron (AS) is a premier national research facility providing Australia, New Zealand and the broader region with access to world-class instrumentation and advanced analytical techniques. Synchrotrons worldwide have established themselves as invaluable tools for drug discovery and biological innovation, and the AS is no different. The Australian Synchrotron’s capabilities provide significant data regarding the molecular and structural dynamics of complex biological systems. These enable insights from mapping drug-target interactions at the atomic level to visualising physiological responses within tissues and organisms. The following article outlines these capabilities and their application to drug discovery in more detail.

Microbiology AustraliaVol. 46(2)
Australian Synchrotron (AU)
Australian Nuclear Science and Technology Organisation, Australian Synchrotron
Zero hunger
Openalex Percentile: Top 89%
Genetics, Bioinformatics, and Biomedical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.